Literature DB >> 16021865

Sustained CD4 responses after virological failure of protease inhibitor-containing therapy.

S G Deeks1, R M Grant.   

Abstract

This article explores current controversies related to 'discordant' responses to antiviral therapy, that is to say, patients with a sustained CD4 cell response despite virological failure. Observational clinical data of patients receiving protease inhibitor-based therapy who had a sustained CD4 cell count even with incomplete viral suppression will be presented, as well as possible mechanisms and clinical implications.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 16021865

Source DB:  PubMed          Journal:  Antivir Ther        ISSN: 1359-6535


  7 in total

Review 1.  HIV protease inhibitors impact on apoptosis.

Authors:  Stacey A Rizza; Andrew D Badley
Journal:  Med Chem       Date:  2008-01       Impact factor: 2.745

2.  Analyses of HIV-1 drug-resistance profiles among infected adolescents experiencing delayed antiretroviral treatment switch after initial nonsuppressive highly active antiretroviral therapy.

Authors:  Allison Agwu; Jane C Lindsey; Kimberly Ferguson; Haili Zhang; Stephen Spector; Bret J Rudy; Stuart C Ray; Steven D Douglas; Patricia M Flynn; Deborah Persaud
Journal:  AIDS Patient Care STDS       Date:  2008-07       Impact factor: 5.078

3.  HIV protease inhibitors provide neuroprotection through inhibition of mitochondrial apoptosis in mice.

Authors:  Toshio Hisatomi; Toru Nakazawa; Kousuke Noda; Lama Almulki; Shinsuke Miyahara; Shintaro Nakao; Yasuhiro Ito; Haicheng She; Riichiro Kohno; Norman Michaud; Tatsuro Ishibashi; Ali Hafezi-Moghadam; Andrew D Badley; Guido Kroemer; Joan W Miller
Journal:  J Clin Invest       Date:  2008-06       Impact factor: 14.808

4.  Mortality associated with discordant responses to antiretroviral therapy in resource-constrained settings.

Authors:  Suely Hiromi Tuboi; Antonio Guilherme Pacheco; Lee H Harrison; Roslyn A Stone; Margaret May; Martin W G Brinkhof; François Dabis; Matthias Egger; Denis Nash; David Bangsberg; Paula Braitstein; Constantin T Yiannoutsos; Robin Wood; Eduardo Sprinz; Mauro Schechter
Journal:  J Acquir Immune Defic Syndr       Date:  2010-01       Impact factor: 3.731

5.  Effective T-cell responses select human immunodeficiency virus mutants and slow disease progression.

Authors:  A J Frater; H Brown; A Oxenius; H F Günthard; B Hirschel; N Robinson; A J Leslie; R Payne; H Crawford; A Prendergast; C Brander; P Kiepiela; B D Walker; P J R Goulder; A McLean; R E Phillips
Journal:  J Virol       Date:  2007-04-04       Impact factor: 5.103

6.  Cost effectiveness of option B plus for prevention of mother-to-child transmission of HIV in resource-limited countries: evidence from Kumasi, Ghana.

Authors:  Adam VanDeusen; Elijah Paintsil; Thomas Agyarko-Poku; Elisa F Long
Journal:  BMC Infect Dis       Date:  2015-03-18       Impact factor: 3.090

7.  AIDS and drug rationing.

Authors:  Pooneh Salari Sharif; Mahshad Noroozi
Journal:  J Med Ethics Hist Med       Date:  2010-03-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.